COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 50 of 1953 for:    cancer vaccine

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01998542
Recruitment Status : Completed
First Posted : November 29, 2013
Last Update Posted : January 23, 2020
Information provided by (Responsible Party):
Immunovative Therapies, Ltd.

Brief Summary:
The purpose of this study is to determine the safety and tumor debulking efficacy of personalized anti-cancer vaccine AlloVax(TM) in Subjects with confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who cannot be treated with surgery, chemotherapy or radiation. AlloVax(TM) is a personalized anti-cancer vaccine combining Chaperone Rich Cell Lysate (CRCL) as a source of tumor antigen prepared from patient's tumor and AlloStim(TM) as an adjuvant. The combination of CRCL and AlloStim(TM) is designed to provide cross-reactivity of alloantigen specific recognition with tumor-specific recognition. All the key components necessary to develop tumor-specific immunity by creating the inflammatory environment necessary to overcome the HNC immunosuppressive environment, breaking tumor immune tolerance, and provision of specific HNC antigens for generation of a specific adaptive anti-tumor response.

Condition or disease Intervention/treatment Phase
Cancer of Head and Neck Squamous Cell Carcinoma of the Head and Neck Biological: AlloVax Biological: CRCL Biological: AlloStim Phase 2

Detailed Description:
This is a Phase II study following up on a previous Phase I/II study in chemotherapy refractory metastatic disease with <90 day survival expectancy. In the Phase I/II study all patients progressed using RECIST criteria. However, 11/42 (26%) were alive at 1yr and 9/42 (21%) alive at 2 yr. Therefore, CT scans did not correlate with clinical presentation and "pseudo-progression" was suspected. This study was designed to select subjects with visible tumor burden on the head, neck or tongue that could be measured and photographed so as not to rely solely on CT scans to determine anti-tumor debulking efficacy. Subjects are initially primed with intradermal AlloStim(TM) injections creating systemic anti-allo-specific cellular immunity. Tumor biopsy samples taken prior to dosing were processed into personalized Chaperone Rich Cell Lysate (CRCL) vaccine containing enriched heat shock proteins which are believed to chaperone tumor-specific neoantigens . AlloStim(TM) was then injected with CRCL into primed subjects to create tumor-specific cellular immunity. Subsequently, subjects are infused with intravenous AlloStim(TM) to cause extravasation of memory cells to the tumor lesions. The protocol including intradermal AlloStim(TM) day 0, 3, 7, 10. Intradermal AlloStim(TM)+CRCL on days 14, 17, 21, 24. Intravenous AlloStim(TM) day 28. This experimental treatment schedule will continue for 3 cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: 12 subjects with externally measurable disease
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study Designed To Evaluate Safety and Tumor Debulking Mechanism of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.
Actual Study Start Date : January 2016
Actual Primary Completion Date : June 1, 2017
Actual Study Completion Date : November 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AlloStim+CRCL
AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
Biological: AlloVax
Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
Other Name: CRCL and AlloStim

Biological: CRCL
autologous tumor-derived chaperone protein mixture
Other Names:
  • Chaperone Rich Cell Lysate
  • CRCL injection

Biological: AlloStim
AlloStim (ID) injection AlloStim (IV) infusion
Other Names:
  • AlloStim ID
  • AlloStim IV

Primary Outcome Measures :
  1. Tumor Response [ Time Frame: baseline, every 28 days for 5 months (CT scan confirmation at baseline and day 90 and day 150) ]
    Tumor response evaluation by clinical exam including photographs of visible tumor lesions on head, neck and/or tongue (endoscopic) and by CT scan assessment for change in target lesion tumor volume (TV). TV is defined as the volume occupied by macroscopic visible target lesion in two longest cross-sectional diameters.

Secondary Outcome Measures :
  1. Anti-tumor immune response [ Time Frame: baseline, 30 days after the last dose ]
    change in tumor pathology and immune cell inflitration

  2. Anti-Tumor Response [ Time Frame: baseline and 30 days after the last dose ]
    expression of CTLA4.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult males and female patients aged 18 to 70 years old, inclusive, at screening visit.
  2. Patients with histopatholologically or cytologically confirmed diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) that is incurable with surgery, chemotherapy or radiation. No nasopharyngeal primaries.
  3. Patients must have a tumor safely accessable for biopsy resulting in a minimum of 0.1 g of tumor sample for CRCL processing.
  4. Patients must have visible external tumors measurable with at least one lesion deemed to be safely accessible for serial biopsy.
  5. ECOG ≤2.
  6. The result of screening test were in the criteria:

    6.1 Adequate organ function including:

    A. Marrow:

    • WBC >3000/mm3
    • Platelets >100,000/mm3.
    • Absolute neutrophil count ≥ 1,500/mm³
    • Hemoglobin ≥ 10.0 g/dL (transfusion allowed)

    B. Hepatic:

    • Serum Total bilirubin < 2 x ULN mg/dL,
    • ALT (SGPT) / AST (SGOT) ≤3 x upper limit of normal (ULN).

    C. Renal:

    • Serum creatinine (SCR) <2.0 x ULN, or
    • Creatinine clearance (CCR) >30 mL/min.

    6.2 All patients have a pre-study echocardiogram without significant abnormalities or Ejection fraction >50%.

    6.3 All patients must be screened to be negative for HIV1, HIV2, HTLVI, HTLVII, HBV, HCV and RPR (syphilis).

    6.4 Women of child-bearing potential must have a negative urine or serum pregnancy test result within 72 hours prior to the start of study drug administration.

  7. All patients of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product.
  8. Patients must have the ability to understand the study, its inherent risks, side effects and potential benefits and be able to give written informed consent to participate.

Exclusion Criteria:

  1. Clinical evidence or radiological evidence of nasopharyngeal primaries.
  2. Clinical evidence or radiological evidence of brain metastasis.
  3. History of severe hypersensitivity to monoclonal antibody drugs or any contraindication to any of the study drugs.
  4. Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis).
  5. Prior experimental therapy or cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine).
  6. Clinical requirement for systemic steroids or current immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month of study entry.
  7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, requiring parenteral antibiotics, symptomatic congestive heart failure, severe myocardial insufficiency, cardiac arrhythmia
  8. All infections must be resolved and the patient must remain a febrile for seven days prior to being placed in the study.
  9. History of blood transfusion reactions.
  10. Psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation.
  11. Pregnant or breast feeding.

The patient will discontinuation from the participation in the study:

  1. Less than 12 doses of CRCL able to be produced
  2. Tumor sample for CRCL processing contains less than 80% tumor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01998542

Layout table for location information
National Cancer Institute of Thailand
Bangkok, Thailand
Sponsors and Collaborators
Immunovative Therapies, Ltd.
Layout table for investigator information
Study Director: Michael Har-Noy, Dr. Immunovative Therapies, Ltd.
Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Immunovative Therapies, Ltd. Identifier: NCT01998542    
Other Study ID Numbers: ITL-010-HNC
First Posted: November 29, 2013    Key Record Dates
Last Update Posted: January 23, 2020
Last Verified: August 2016
Keywords provided by Immunovative Therapies, Ltd.:
Head and neck cancers
tumor vaccine
personalized anti-cancer vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Squamous Cell
Disease Attributes
Pathologic Processes